EurekAlert! National Institutes of Health - cloned-NIH - News from NIH

Latest news releaess from NIH

NIH Research News

Updates every hour. Last Updated: 2-Sep-2025 00:11 ET (2-Sep-2025 04:11 GMT/UTC)

NIH-funded study identifies potential new stroke treatment

NIH/National Institute of Neurological Disorders and Stroke

In a preclinical study, rodents treated with uric acid showed improved long-term outcomes after acute ischemic stroke. The findings suggest that the treatment may work as an add-on therapy to standard stroke treatments in humans. The study was funded by the National Institutes of Health (NIH) and published in Stroke.

Journal: Stroke
Funder: NIH/National Institute of Neurological Disorders and Stroke

Topical steroid withdrawal diagnostic criteria defined by NIH researchers

NIH/National Institute of Allergy and Infectious Diseases
Peer-Reviewed Publication

Researchers at the National Institutes of Health (NIH) have determined that dermatitis resulting from topical steroid withdrawal (TSW) is distinct from eczema and is caused by an excess of an essential chemical compound in the body. Scientists from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) identified treatments that could be studied in clinical trials for the condition based on their potential to lower levels of the chemical compound—called nicotinamide adenine dinucleotide (NAD⁺), a form of vitamin B3. The findings were published today in the Journal of Investigative Dermatology.

Journal: Journal of Investigative Dermatology
Funder: NIH/National Institute of Allergy and Infectious Diseases

Tecovirimat is safe but ineffective as treatment for clade II mpox

NIH/National Institute of Allergy and Infectious Diseases
Reports and Proceedings

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical trial sponsored by the National Institutes of Health (NIH). The trial enrollment was stopped in late 2024 when an interim analysis showed that tecovirimat monotherapy was ineffective in the study population. Detailed results were presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

Funder: NIH/National Institute of Allergy and Infectious Diseases

Spotlight on UPFs: NIH explores link between ultra-processed foods and heart disease

NIH/National Heart, Lung and Blood Institute

From hot dogs and potato chips to chicken nuggets and sugary sodas, Americans are eating more ultra-processed foods (UPFs) than ever. Researchers estimate that up to 70% of the U.S. diet is composed of foods that are ultra-processed – meaning an excess number of substances have been added during manufacturing to help them taste better, look better, and last longer.

Journal: The Lancet

NIH-funded research team engineers new drug targeting pain sensation pathway

NIH/National Institute of Neurological Disorders and Stroke
Peer-Reviewed Publication

A research team funded by the National Institutes of Health (NIH) has developed a medication that shows promise in treating acute and chronic pain. The drug, known as VIP36, targets the body’s cannabinoid receptor type 1 (CB1). It was found to be effective in three different animal models for pain and does not appear to cause the harmful side effects that have frustrated other efforts to target CB1. These results enhance understanding of how to design safer and more effective drugs targeting cannabinoid receptors and are an important step towards developing novel, non-addictive treatments for pain.

Journal: Nature
Funder: NIH/National Institutes of Health

4
5
6
7